BioLife - רווח נקי למניה אחת בשנים עשר החודשים האחרונים BLFS

The annual percentage change in EPS TTM for BioLife Solutions, Inc. (BLFS) demonstrates how its own cryogen production plants in the US impact supply stability. The current 986.30 reflects the metric's baseline level. The company is currently pivoting toward high-margin software, moving away from low-cost equipment. Simultaneously, BioLife Solutions, Inc. (BLFS) is strengthening its status as a key partner in the gene therapy sector by supplying specialized biomaterial preservation systems.

This indicator measures the percentage shift in net earnings per share over the last twelve months relative to the same period last year, allowing investors to filter out market noise and identify the real earnings trend. By analyzing the percentage change in EPS over a rolling year, an investor can see how the integration of BioLife Solutions, Inc. (BLFS) proprietary media into gene therapy protocols converts into actual profit growth.